Literature DB >> 7370238

Evidence of a specific complex between adriamycin and negatively-charged phospholipids.

E Goormaghtigh, P Chatelain, J Caspers, J M Ruysschaert.   

Abstract

Membrane-model systems (monolayers, small unilamellar vesicles) were used to study the interaction between adriamycin (ADM) and phospholipids. Adsorption of 3H-labeled adriamycin on different phospholipid monolayers demonstrated the specificity of adriamycin for negatively-charged phospholipids (cardiolipin, phosphatidylserine, phosphatidic acid). The stoichiometry has been found to be approx. 2 mol (1.8) adriamycin per mol cardiolipin and approx. 1 mol (0.75) adriamycin per mol phosphatidylserine and phosphatidic acid. No adsorption was detected with neutral lipids. Surface-potential measurements confirm the formation of a complex stabilized by electrostatic interactions without penetration of the drug into the lipid lipophilic phase. Some adriamycin derivatives were used to discriminate between the ionized hydrophilic and hydrophobic contributions in the complex formation. The absorption spectrum of adriamycin in the presence of cardiolipin resembles the behavior of the ADM-DNA complex. Moreover, the association constants of the two complexes are very similar (cardiolipin-ADM, 1.6 . 10(6) . M-1; ADM-DNA, 2.4 . 10(6) . M-1). To explain the high affinity of cardiolipin for adriamycin, we proposed that two essential interactions are responsible for the complex stabilization: an electrostatic interaction between the protonated amino groups of the sugar residues and the ionized phosphate residues, and an interaction between adjacent anthraquinone chromophores. These data strongly suggest competitive behavior between a membrane site and the target. Consequently, it must be assumed that the lipidic components of the cell membrane structure may be an important determinant in the behavior of adriamycin. This observation should be kept in mind in the building of new derivatives.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7370238     DOI: 10.1016/0005-2736(80)90145-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  39 in total

Review 1.  Doxorubicin effects on contractile structures and molecules.

Authors:  R Colombo; A Milzani; A Necco; G Vailati
Journal:  Cytotechnology       Date:  1990-01       Impact factor: 2.058

2.  Changes in the electrochemical composition of cochlear fluids after intracisternal application of doxorubicin in the rat.

Authors:  I Sziklai; E Ferrary; A Loiseau; O Sterkers; C Amiel
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

3.  Interactions of adriamycin, cytochrome c, and serum albumin with lipid monolayers containing poly(ethylene glycol)-ceramide.

Authors:  Hongxia Zhao; Patricia M Dubielecka; Tim Söderlund; Paavo K J Kinnunen
Journal:  Biophys J       Date:  2002-08       Impact factor: 4.033

4.  Inhibition of Epstein-Barr-virus-transformed human chronic lymphocytic leukaemic B cells with monoclonal-antibody-adriamycin (doxorubicin) conjugates.

Authors:  Z Zhu; J Kralovec; T Ghose; M Mammen
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

5.  The influence of lipoic acid on adriamycin induced nephrotoxicity in rats.

Authors:  Kumaravel Palanichamy Malarkodi; Andithangal Venkatesan Balachandar; Palaninathan Varalakshmi
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

6.  Selectivity of the anthracyclines for negatively charged model membranes: role of the amino group.

Authors:  T G Burke; A C Sartorelli; T R Tritton
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 7.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

Review 8.  Mitochondrial targeting of electron scavenging antioxidants: Regulation of selective oxidation vs random chain reactions.

Authors:  Valerian E Kagan; Peter Wipf; Detcho Stoyanovsky; Joel S Greenberger; Grigory Borisenko; Natalia A Belikova; Naveena Yanamala; Alejandro K Samhan Arias; Muhammad A Tungekar; Jianfei Jiang; Yulia Y Tyurina; Jing Ji; Judith Klein-Seetharaman; Bruce R Pitt; Anna A Shvedova; Hülya Bayir
Journal:  Adv Drug Deliv Rev       Date:  2009-08-27       Impact factor: 15.470

Review 9.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

10.  Adriamycin induced resistance of sensitive K 562 cells to natural killer lymphocyte attack.

Authors:  H Benoist; C Madoulet; J C Jardillier; A Desplaces
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.